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Abstract
 
Interferon (IFN)-
 
  
 
is necessary for tumor immunity, however, its initial cellular source is un-
known. Because 
 
   
 
T cells primarily produce this cytokine upon activation, we hypothesized
that they would provide an important early source of IFN-
 
  
 
in tumor immunosurveillance. To
address this hypothesis, we first demonstrated that 
 
   
 
T cell–deficient mice had a significantly
higher incidence of tumor development after challenge with a chemical carcinogen methyl-
cholanthrene (MCA) or inoculation with the melanoma cell line B16. In wild-type mice, 
 
   
 
T
cells were recruited to the site of tumor as early as day 3 after inoculation, followed by 
 
   
 
T
cells at day 5. We then used bone marrow chimeras and fetal liver reconstitutions to create
mice with an intact 
 
   
 
T cell repertoire but one that was specifically deficient in the capacity to
produce IFN-
 
 
 
. Such mice had a higher incidence of tumor development, induced either with
MCA or by inoculation of B16 melanoma cells, compared with mice with IFN-
 
 
 
–competent
 
   
 
T cells. Moreover, genetic deficiency of 
 
   
 
T cells resulted in impaired IFN-
 
  
 
production
by tumor antigen-triggered 
 
   
 
T cell upon immunization with tumor lysate. These results
demonstrate that 
 
   
 
T cells can play a necessary role in tumor immunity through provision of
an early source of IFN-
 
  
 
that in turn may regulate the function of tumor-triggered 
 
   
 
T cells.
Key words: cytokines • immunosurveillance • immune regulation • tumor 
immunosurveillance
 
Introduction
 
IFN-
 
  
 
is a necessary cytokine in the innate and adaptive
immune responses that protect against tumor development
(1, 2). Endogenously produced IFN-
 
  
 
forms the basis of a
tumor surveillance system against the development of pri-
mary chemically induced sarcomas (3, 4). For example,
mice deficient in the IFN-
 
  
 
receptor or in Stat1, required
for IFN-
 
  
 
signaling, develop tumors more rapidly and with
greater frequency in response to the chemical carcinogen
methylcholanthrene (MCA)
 
* 
 
when compared with wild-
type mice. Lymphocytes also are necessary for immunity to
spontaneously induced tumors, with their role dependent
upon IFN-
 
  
 
synthesis (5). Tumor cells themselves are the
major target of the action of IFN-
 
 
 
, as determined using
IFN-
 
 
 
–insensitive tumor cell lines and a transplant tumor
model (6).
Several immunological and nonimmunological mecha-
nisms have been proposed to explain the effect of IFN-
 
  
 
in
tumor immunity (1). Perhaps most importantly, IFN-
 
  
 
is
critical for the development of an effective adaptive im-
mune response, primarily directing the balance of Th1/
Th2 cytokines toward protection. Notably, the primary
cellular source for the initial production of IFN-
 
  
 
has not
yet been defined. It has been proposed that innate cells or
innate-like lymphocytes, such as NK, NK T, and 
 
   
 
T
cells, might provide the early source of this cytokine (2).
 
   
 
T cells have many features that distinguish them from
 
   
 
T cells (7–9). Most of the former have a phenotype of
spontaneous activation with a fast turnover rate in vivo
(10), and they quickly expand upon pathogen challenge in
the first few days after infection (11–14). 
 
   
 
T cells also
regulate CD4
 
  
 
and CD8
 
  
 
T cell function. For example, in
a Coxsackie virus infection model, V
 
 
 
1 cells direct CD4
 
 
 
T cells toward a dominant Th2 response, whereas V
 
 
 
4 cells
bias them toward a dominant Th1 response (15). In a simi-
lar manner, 
 
   
 
T cells are responsible for the establishment
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*
 
Abbreviation used in this paper:
 
 MCA, methylcholanthrene.T
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of a protective CD8
 
  
 
memory response during 
 
Listeria
monocytogenes
 
 infection (16), whereas 
 
   
 
T cell–deficient
mice have an inadequate CD8
 
  
 
T cell immune response
against 
 
Encephalitozoon cuniculi
 
 infection (17).
 
   
 
T cells provide the host with several potential advan-
tages over conventional lymphocytes in host protection
against tumors. CD8
 
  
 
T cells recognize processed peptide
antigens in the context of self-MHC class I molecules that
may have impaired expression on tumor cells, thereby ren-
dering the tumor immunologically invisible to 
 
   
 
T cells.
By contrast, 
 
   
 
T cells recognize antigens directly, with no
requirement for antigen processing or presentation (8, 9).
More recently, 
 
   
 
T cells have been shown to recognize
the MHC class I–related molecules MICA and MICB,
which are induced by stress resulting from infection or in-
jury, or by cellular transformation (18, 19). These mole-
cules have been shown to be stimulatory ligands for the
NK cell receptor NKG2D that is also found on 
 
   
 
T cells
(20, 21). Moreover, skin-associated 
 
   
 
T cells play an im-
portant role in preventing tumor development through
NKG2D-mediated cytolytic mechanisms (22).
To precisely define the role of 
 
   
 
T cells in the protec-
tive immune responses against tumor development, we an-
alyzed tumor formation and growth in B6 TCR
 
 
 
-deficient
(TCR
 
 
 
 
 
/
 
 
 
) mice compared with wild-type mice, as well as
in bone marrow chimeras or fetal liver–reconstituted mice
in which 
 
   
 
T cells selectively lack the ability to produce
IFN-
 
 
 
. We demonstrate that 
 
   
 
T cells play a critical role
in the protective immune response against tumor develop-
ment by providing an important early source of IFN-
 
  
 
that
in turn regulates 
 
   
 
T cell effector function.
 
Materials and Methods
 
Mice.
 
C57BL/6J (B6), C57BL/6J-Tcrb
 
tm1Mom 
 
(B6 TCR
 
 
 
-
deficient mice [TCR
 
 
 
 
 
/
 
 
 
]), C57BL/6J-Tcrd
 
tm1Mom 
 
(B6 TCR
 
 
 
 
 
/
 
 
 
),
and C57BL/6-Ifngtm1Ts (B6 IFN-
 
 
 
–deficient [IFN-
 
 
 
   
 
]) mice
were purchased from The Jackson Laboratory. B6 IFN-
 
 
 
 
 
/
 
 
 
mice and B6 TCR
 
 
 
 
 
/
 
  
 
mice were bred to create B6 TCR
 
 
 
 
 
/
 
 
 
IFN-
 
 
 
 
 
/
 
  
 
double deficient mice. For bone marrow chimeras, the
donors and recipients are listed in Table I. All animals were main-
tained under specific pathogen-free conditions and used at 6–8
wk of age unless specifically mentioned.
 
Reagents.
 
Recombinant murine IL-2 and IL-12 were pur-
chased from R&D Systems. Anti–mouse mAb used for phenotypic
and cytokine analyses were all purchased from BD Biosciences.
 
Tumor Models.
 
Induction of fibrosarcomas by injection with
MCA has been described (3, 22). In brief, MCA was dissolved in
peanut oil overnight and sex- and age-matched groups of mice
were injected intradermally in the flank (75 
 
 
 
g MCA/mouse).
Fibrosarcoma development was recorded weekly. Alternatively,
B16 F0 melanoma cells (provided by M. Mamula, Yale School of
Medicine, New Haven, CT) were injected subcutaneously (5 
 
 
 
10
 
4 
 
tumor cells/ mouse) and tumor growth was observed and re-
corded daily for over 3 wk.
 
Bone Marrow Chimeras.
 
Bone marrow chimeras were pre-
pared according to a previously described protocol (23). In brief,
recipients were twice irradiated with 500 rads, with a 3-h interval
between doses (total 1,000 rads). Donor bone marrow cells
(mixed equally from two donors, see Table I for details) were in-
 
jected intravenously into recipients (10
 
7 
 
cells/ mouse). Antibiotics
were added to the drinking water for the first 5 wk after reconsti-
tution. At 12 wk after reconstitution, mice were injected intra-
dermally in the flank with MCA or subcutaneously with B16
melanoma cells and monitored for tumor development as de-
scribed above. At the time of death, splenocytes were used to ex-
amine T cell composition and determine the ability of T cell sub-
sets (
 
   
 
vs. 
 
   
 
T cells) to produce IFN-
 
  
 
as described below.
 
Fetal Liver Reconstitution.
 
Fetal liver cell reconstitution was
performed as previously described (24). Accordingly, donor cells
were isolated from the fetal livers at 14 d of gestation, and 10
 
7 
 
un-
fractioned fetal liver cells in sterile PBS were injected intraperito-
neally into 3-d-old recipients. After 8 wk of reconstitution, mice
were used for tumor implantation as described above. At the time
of sacrifice (3 wk after tumor inoculation), splenocytes were used
to examine T cell composition and determine the ability of T cell
subsets (
 
   
 
and 
 
   
 
T cells) to produce IFN-
 
  
 
as described below.
 
Cell Composition and Intracellular Cytokine Staining.
 
To test the
composition of T cell subsets from bone marrow chimeras and
from mice reconstituted with fetal liver cells, splenocytes were
stained with anti-CD3 (CyChrome), anti–
 
   
 
TCR (FITC), and
anti–
 
   
 
TCR (PE) followed with FACS
 
® 
 
analysis. To confirm
the success of the selective depletion of the ability of 
 
   
 
T cells to
produce IFN-
 
 
 
, 2   106/ml splenocytes were cultured with 10
 g/ml anti-CD3 and 1  g/ml anti-CD28 in the presence of
5 ng/ml IL-12 as described in our previous studies (25). After 4 d
of culture, cells were restimulated with anti-CD3 and anti-CD28
in the presence of brefeldin A for 6 h for intracellular IFN- 
staining as detailed below.
Intracellular Cytokine Staining. For bone marrow chimeras and
for mice reconstituted with fetal liver cells, splenocytes cultured
as described above were activated with anti-CD3 and anti-CD28
for 6 h with brefeldin A added for the last 2 h. Cells were stained
with CyChrome anti-  , and FITC anti–   TCR antibodies
followed with fixation in 2% formaldehyde in PBS. Cells were
then permeabilized and stained with PE anti–IFN-  as previously
described (25). Gating was performed on    and    T cells and
the percentage of IFN-   cells was reported.
Immunohistochemical Staining. Melanoma cells (B16-F0) were
inoculated into the right flank of C57BL/6 mice at the age of
7 wk. The mice were killed at various time points after injection
(days 1, 3, 5, 7, 9, and 11, respectively). The injected sites, in-
cluding skin and subcutaneous tissues and tumors per se, were re-
sected and cut across the center. Tissues were then embedded in
OCT compound, frozen in liquid nitrogen, and mounted for
cryostat sectioning for immunohistochemical staining. 8- m cryo-
stat sections were fixed in cold acetone for 10 min and rinsed
three times with cold PBS for 10 min to remove OCT. Endoge-
nous peroxidase was quenched with 1.5% H2O2 for 10 min at
room temperature. The sections were blocked with 10% normal
goat serum for 30 min in a humidified chamber and then incu-
bated with primary antibodies against TCR-  , CD4, and CD8 
for 2 h at room temperature. After washing twice, a biotinylated
secondary antibody was added and incubated for 30 min, fol-
lowed by incubation with ABC for 30 min and the substrate 3 ,3 
diaminobenzidine for 5 min, combined with hematoxylin coun-
terstaining for 10 s. Sections of B6 mouse spleen were incubated
with anti–mouse TCR-  , CD4, and CD8  antibodies as posi-
tive controls. Normal goat serum without primary antibodies was
used as a negative control. In addition, spleen tissues of TCR  / 
mouse were stained with anti–mouse TCR-   as an additional
negative control. Positive cells were counted in five random high
power fields under a Nikon microscope.T
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Preparation of Cell Suspensions from the Site of Tumor Injection.
C57BL/6 mice (n   10) at age 7 wk were injected with 105
B16F0 melanoma cells. At day 3 after inoculation, small pieces
of shaved skin were resected and digested with trypsin-GNK
solution (0.29% trypsin, 0.86% NaCl, 0.041% KCl, and 0.1%
glucose) at 37 C for 2 h, and then further treated with collage-
nase/hyaluronidase digestion solution buffer (0.27% collagenase,
0.025% hyaluronidase, 1% DNase, 0.01% Hepes, 0.01% sodium
pyruvate in RPMI) for 2 h at 37 C as previously described (26).
The digested skin was filtered through a 40-mM cell strainer
(Becton Dickinson) and a single cell suspension was obtained
containing resident cells and infiltrating cells (26). Cells were
stained with anti–CD3-CyChrome and anti–   TCR FITC,
and cells were then fixed with 2% formaldehyde and further
stained for intracellular IFN-   (anti–IFN-   PE) as described
above.
Tumor Antigen–triggered    T Cell IFN-  Production. Cul-
tured B16 F0 cells were digested with trypsin and washed with
PBS, and then sonicated and centrifuged. The protein concentra-
tion of the supernatant was determined by a Bio-Rad kit (Bio-
Rad Laboratories) and adjusted to 2 mg/ml. Age- and sex-
matched B6 and B6 TCR  /  mice were immunized with 100
 g tumor lysate emulsified in CFA in the hind footpad and re-
challenged with the same concentration of tumor lysate emulsi-
fied in IFA 14 d later. On day 21, the mice were killed and drain-
ing lymph node cells were cultured with 100  g/ml tumor lysate.
Intracellular cytokine staining for the analysis of IFN-  produc-
tion by CD4  and CD8  T cells was performed as described
above.
Statistics. Statistical significance was evaluated by two-tailed,
unpaired Student’s t test or nonparametric analysis if SD were sig-
nificantly different between the two compared groups using soft-
ware InStat 2.03 for Macintosh (GraphPad Software). The inci-
dence of tumor development was compared and analyzed using
the log rank test, performed by GraphPad Prism Version 3.0a for
Macintosh (GraphPad Software). Throughout the text, figures,
and legends, the following terminology was used to denote statis-
tical significance: *, P   0.0001 or P   0.001; **, P   0.01; ***,
P   0.05.
Results
   T Cells Are Critical for Preventing Primary and Trans-
plantable Tumor Development. Both lymphocytes and IFN- 
are critical for tumor immunosurveillance, with overlap-
ping effects (5).    T cells are critical for preventing MCA-
induced fibrosarcoma development in susceptible strains of
mice (22). To test the role of    T cells in preventing tu-
mor development in a resistant strain, sex- and age-
matched B6 wild-type (n   28) and B6 TCR  /  mice
(n   24) were injected with MCA in the flank (75  g/
mouse), and tumor development was observed and mea-
sured weekly. Mice lacking    T cells had a significantly
greater susceptibility to MCA-induced tumors, with 80%
of the mice showing tumor development (tumor size larger
than 4   4 mm) when compared with wild-type TCR  / 
mice (20%; Fig. 1 A, p   0.01). Tumors between 2   4
mm without progression in 3 wk were excluded from anal-
ysis, as these may result from neovascularization, a IFN- –
mediated process (2).
To further explore the protective role of    T cells in a
transplantable tumor model, T cell–intact (WT, n   12) or
T cell subset–deficient mice (TCR  / , n   18; TCR  / ,
n   21) and IFN-  /  mice (n   15) were injected with
the melanoma cell line B16 F0 subcutaneously at low doses
(5   104 cells/mouse). In preliminary studies, titration of
the number of injected tumor cells in B6 mice demon-
strated that with this dose of tumor cells, only 20–30% of T
cell–intact, wild-type mice showed tumor growth (unpub-
lished data). Both    and    T cells contributed to the
protective immune response against tumor development in
vivo, indicating a nonredundant role for    T cells in trans-
plantable melanoma growth (Fig. 1 B). Consistently, IFN-
  /  mice also showed a higher susceptibility to tumor
growth, reaffirming the critical role of IFN-  in immuno-
surveillance (3, 5, 6).
Figure 1.    T cells are necessary to prevent tumor development. (A)
Protective role of    T cells in the MCA-induced tumor model. Sex- and
age-matched B6 wild-type (WT, n   28) and B6 TCR -deficient mice
(TCR  / , n   24) were injected with 75  g MCA/mouse in the flank.
Tumor development was recorded weekly after injection. Tumor size
 4   4 mm was considered positive as previously described (reference
3). (B) Protective role of    T cells and IFN-  in the B16 melanoma
transfer model. Four groups of age- and sex-matched mice (B6 wild-type
mice, n   12; B6 TCR -deficient mice, n   18; B6 TCR -deficient
mice, n   21; B6 IFN- –deficient mice, n   15), all at 8 wk of age were
injected subcutaneously with 5   104 B16 F0 melanoma cells and tumor
growth was recorded daily. The percentage of mice with tumors 21 d af-
ter injection is shown. Data represent mean   SD of three independent
experiments. *, P   0.001; **, P   0.01.T
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   T Cells Are Recruited to the Tumor Injection Site Earlier
Than    T Cells and Produce IFN-  Ex Vivo.     T cells
respond to pathogen invasion and quickly expand in the
first few days of infection, and thus these T cells may con-
tribute to early pathogen protection (11–14). To investi-
gate whether    T cells are early infiltrating immune cells
responding to tumor invasion, a series of tissue samples of
B16 melanoma injection sites were analyzed by immuno-
histochemical staining using antibodies against    TCR or
CD4  or CD8  T cells. TCR-    cells were observed in
subcutaneous tissue as early as day 3, and the infiltration of
these cells gradually increased and peaked at day 7 (Fig.
Figure 2.    T cells are recruited
earlier than     T cells into tumor
sites. B6 wild-type mice were inocu-
lated with B16 F0 melanoma cells
(5   104 cells/mouse) and at different
time points after inoculation, the tu-
mor injection site was frozen and
stained with specific antibodies
against TCR   , CD4, and CD8 as
described in Materials and Methods.
(A) One slide from each time point
depicting the staining for each cell
type is shown. Examples of positive
cells are indicated by arrows. (B)
Summary of mean   SD of the num-
ber of positive cells per high power
field is shown. (C) Cell suspensions
were prepared from pools of 10 tis-
sues collected from tumor injection
sites and cells were stained with anti-
CD3 and anti–   TCR. A represen-
tative example of a flow cytometry
plot is shown. (D) Stained cells (from
C) were fixed and permeabilized for
intracellular IFN-  (PE) staining. A
representative plot is shown.T
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2 A, top). In contrast, CD4  or CD8  T cell infiltration
was not observed at day 3, although these    T cells ap-
peared at day 5 and gradually increased in number until
reaching a peak at day 11 (Fig. 2 A, middle and bottom,
and B). To test whether the infiltrating    T cells produce
IFN-  in situ, B6 mice were injected with B16 melanoma
cells, the tissue at the tumor injection site was digested, and
infiltrating cells were stained directly for anti–   TCR and
anti-CD3 followed by intracellular IFN-  staining. Consis-
tent with our immunohistological staining, most of the in-
filtrating CD3  lymphocytes were    T cells (Fig. 2 C). A
minor population of CD3  T cells (0.19%) might be NK T
cells because they did not stain positive for    TCR (un-
published data). Strikingly, most IFN- –producing cells
were    T cells and only 0.07% of IFN-   cells were from
another cell source (Fig. 2 D). These results imply that   
T cells infiltrate tumor sites earlier than    T cells, provid-
ing IFN-  production that may guide the function of   
T cells.
   T Cells Provide an Early Source of IFN-  for a Protective
Immune Response Against Both Primary Tumor Induction and a
Transferred Tumor. Based upon our previous findings that
   T cells predominantly produce IFN-  upon activation
(25, 27), and on the fact that IFN-  plays an essential role in
tumor immunosurveillance (1–3), we hypothesized that the
   T cells that were visualized at the tumor site might play
an important protective role through IFN-  production.
To test this hypothesis, we first prepared bone marrow chi-
meras in which T cell composition is intact (both    and
   T cells), except that the    T cells could (   IFN-  ) or
could not (   IFN-  ) produce IFN- . The detailed com-
position of donors and recipients is shown in Table I, with
   IFN-   animals labeled as the experimental group and
the    IFN-   mice as the control group. As expected, ex-
perimental chimeras (   IFN-  ) were fully reconstituted
with    and    T cells, with the same ratios of    and   
T cells as wild-type controls (Fig. 3 A). Moreover, upon ac-
tivation and restimulation in vitro, only    (52.7%), but not
   (0%), T cells produced IFN-  (Fig. 3 B), indicating the
success of obtaining the expected phenotype in this group.
The cell composition was very similar in the control group
of chimeras (   IFN-  ), although by contrast to the ex-
perimental group, their    T cells were fully capable of
IFN-  production as expected (unpublished data).
Next, we used these chimeras to explore the role in tu-
mor protection of IFN-  produced solely by    T cells.
Here we compared tumor development in reconstituted
animals (n   8–9, 12 wk after reconstitution) to sex- and
age-matched B6 wild-type (n   10), B6 TCR  /  (n  
13), B6 TCR  /  (n   11), and B6 IFN-  /  (n   19)
Table I. Generation of Bone Marrow Chimeras
Group Donors 1 Donors 2 Recipients Expected outcome
Experimental TCR     IFN-     TCR     IFN-        T cells cannot produce IFN- 
Control TCR     IFN-     TCR     IFN-        T cells can produce IFN- 
Bone marrow chimeras were prepared as described in Materials and Methods. Bone marrow cells from TCR  /  mice (normal    T cells without
   T cells) together with bone marrow cells either from TCR  /  IFN-  /  mice (   T cells lack the ability to produce IFN- ) or from TCR  / 
IFN-  /  mice (   T cells can produce IFN- ) in a 1:1 ratio were injected intravenously into irradiated IFN-  /  mice (to eliminate any radio-
resistant source of endogenous IFN- ). All mice were on the B6 background and were age and sex matched. 12 wk after reconstitution, mice were
injected with MCA or with B16 F0 melanoma cells.
Figure 3. Generation and analysis
of bone marrow chimeras. (A)
Composition of    and    T cells in
wild-type mice versus an experi-
mental group of bone marrow chi-
meras. Bone marrow chimeras were
prepared as described in Materials
and Methods using donors and re-
cipients (refer to Table I). At the end
of the experiments, splenocytes from
the experimental group and wild-
type mice were prepared and stained
with FITC anti–   TCR (GL3), PE
anti–   TCR (H57-597), and Cy-
Chrome anti-CD3 (145-2C11). Af-
ter gating on CD3   T cells, the
composition of    and    T cells was analyzed. Two controls and six reconstituted mice are shown. (B) IFN-  production by    and    T cells in bone
marrow chimeras. Splenocytes from bone marrow chimeras (experimental group,    IFN-  ) were cultured with anti-CD3 and anti-CD28 in the pres-
ence of IL-12 for 5 d. Cells were then restimulated with anti-CD3 and anti-CD28 in the presence of brefeldin A for 6 h. After staining with FITC anti–
TCR    and CyChrome anti–TCR   , cells were fixed, permeabilized, and further stained with PE anti–IFN- . After gating on    and    T cells, the
percentage of IFN-   cells was detected (see representative histogram).T
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438    T Cells in Tumor Immunity
mice. At 14 wk after injection with MCA, 70% TCR  / 
and TCR  /  mice showed tumor development (P  
0.05), compared with 30% of wild-type animals (Fig. 4 A,
P   0.05), confirming a nonredundant role for    T cells
in preventing tumors (22). In addition, we observed a sig-
nificantly higher percentage of tumors in the IFN-  / 
mice (Fig. 4 A, P   0.01), consistent with previous find-
ings that IFN-  is essential in tumor Immunosurveillance
in the MCA-induced tumor model (3).
Strikingly, the experimental group of chimeras, in
which the only defect was the ability of    T cells to pro-
duce IFN-  (   IFN-  ), had an incidence of tumor de-
velopment similar to IFN-  /  mice (completely lacking
IFN- ), indicating the importance of IFN-  produced by
   T cells in preventing tumor development. Moreover,
the experimental group of chimeras had a significantly
higher tumor incidence than control chimeras (  
IFN-  ) or wild-type mice (Fig. 4 A, P   0.01), although
mice from the experimental group only differed from
control chimeras or wild-type mice in the ability of their
   T cells to produce IFN- . Thus, our results provide
strong evidence for a necessary role of    T cells in pro-
viding a source of IFN-  for the protective effect pro-
vided by this cytokine.
To further substantiate the requirement for    T cells in
provision of an early source of IFN-  in tumor protection,
Figure 4. IFN-  produced by
   T cells is critical for protec-
tive immune responses against
tumors. (A) Development of
MCA-induced tumors in bone
marrow chimeras and in unma-
nipulated mice. Four groups of
age- and sex-matched mice (B6
wild-type mice, n     10; B6
TCR -deficient mice, n   13;
B6 TCR -deficient mice, n  
11; B6 IFN- –deficient mice,
n   19; all at age 6 wk), and two
groups of age- and sex-matched
bone marrow chimeras (experi-
mental group, n     9; control
group, n   8; 10 wk after re-
constitution) were injected with
MCA (75  g/mouse in the
flank). Animals were observed
weekly and tumor size was mea-
sured with a calimeter. The per-
centage of mice that developed
tumors is shown. Data represent
mean   SD of three indepen-
dent experiments. *, P   0.001;
**, P   0.01. (B) B16 melanoma
model in bone marrow chi-
meras. Bone marrow chimeras
reconstituted as in A were in-
jected with 5    104  B16 F0
cells/mouse and tumor growth
was recorded. The percentage of
mice that developed tumors
21 d after inoculation is shown.
Data represent mean    SD of
three independent experiments.
*, P   0.001; **, P   0.01. (C)
B16 melanoma model in mice
reconstituted with fetal liver
cells. TCR  /  mice were re-
constituted with fetal liver cells
either from B6 TCR  /  mice
(    IFN-  ) or from TCR  / 
IFN-  /  (    IFN-  ). 8 wk
after reconstitution, mice were
inoculated with 5    104 B16
F0 cells/mouse and tumor
growth was recorded. The per-
centage of mice that devel-
oped tumors 21 d after inocula-
tion is shown. Data represent mean   SD of three independent experiments. *, P   0.001; **, P   0.01. (D) Time course of B16 tumor
development in bone marrow chimeras (B) and fetal liver reconstituted mice (C).T
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we again turned to the B16 melanoma transplantable tumor
model. Sex- and age-matched bone marrow chimeras (ex-
perimental:    IFN-  , n   9; control:    IFN-  , n   6)
were inoculated with B16 F0 melanoma cells (5   104
cells/mouse) and tumor growth was monitored daily. At
day 21 after inoculation,  50% (6 out of 9) of the experi-
mental (   IFN-  ) group developed tumors ( 4    4
mm), whereas only 17% of control chimeras (   IFN-  , 1
out of 6) showed sizeable tumor growth (Fig. 4 B, P  
0.01). Moreover,    IFN-   bone marrow chimeras devel-
oped tumors much earlier when compared with    IFN-  
chimeras (Fig. 4 D, P   0.05). This further supports the
notion that    T cells are a critical source of IFN-  in pre-
venting tumor growth in vivo.
Finally, to more firmly establish the role of    T cells in
providing the early source of IFN-  in tumor immunosur-
veillance, we also reconstituted    T cell–deficient mice
with fetal liver cells from mice with an intact    T cell
repertoire, but with or without the capacity to produce
IFN- . The advantage of this system is that T cell subsets
distribute and repopulate similarly to wild-type mice (24).
Moreover, reconstitution takes place as mice mature (dur-
ing the 5–6 wk after the birth), so that experiments can be
performed at ages of 6–8 wk. TCR  /  mice at 3 d of
birth were reconstituted with fetal liver cells (14 d of ges-
tation) either from TCR  /  mice (   T cells can pro-
duce IFN- ; hence, mice are     IFN-  ) or from
TCR  /  IFN-  /  mice (    T cells cannot produce
IFN- ; hence, mice are    IFN-  ). 8 wk after reconsti-
tution, sex- and age-matched mice from both groups (  
IFN-  , n   20;    IFN-  , n   18), along with unma-
nipulated B6 wild-type and B6 TCR  /  mice, were in-
jected with B16 F0 melanoma cells (5   104 cells/mouse)
and tumor growth was observed daily.    IFN-   mice
showed a significantly higher rate of tumor growth than
   IFN-   reconstituted mice (Fig. 4 C, P   0.01), with
significantly earlier kinetics of tumor development (Fig. 4
D, P   0.01), providing further support for the concept
that    T cells provide a necessary source of IFN-  in pro-
tective immunity against tumors.
   T Cells Regulate Tumor Antigen–triggered    T Cell
IFN-  Production. IFN-  is a critical cytokine for direct-
ing both CD4  and CD8  T cell differentiation (28, 29).
These T cells regulate CD4  and CD8  T cell effector
function upon pathogen infection (16, 17). Based upon the
results described above, we next hypothesized that    T
cells might regulate tumor antigen–triggered     T cell
IFN-  production. To address this question, sex- and age-
matched B6 wild-type and B6 TCR  /  mice (n   5 for
both groups) were immunized with B16 F0 cell lysates, fol-
lowed by challenge with identically prepared lysates in IFA
14 d later. The production of IFN-  by     T cells in
draining lymph nodes was then analyzed 7 d later upon re-
stimulation with tumor lysate in vitro. Both CD4  and
CD8  T cells from TCR  /  mice produced significantly
less IFN-  upon tumor antigen restimulation in vitro com-
pared with wild-type mice (Fig. 5 A). The finding is con-
sistent with the previous findings that    T cells are re-
quired to promote IFN-  production by both CD4  and
CD8  T cells (15, 17).
Discussion
It is well established that IFN-  is an essential mediator
for the protective immune response against tumor devel-
opment (1, 3, 5). However, the source of this cytokine
early after tumor challenge has not been identified. NK
cells and certain lymphocytes that have features of both in-
nate and adaptive immune cells, including NK T and    T
cells, are considered to be important for bridging the in-
nate and adaptive immune responses and they might pro-
vide the initial source of IFN-  in tumor protection. This
in turn could facilitate the cascade of the adaptive immune
response and augment later IFN-  production (2). In this
report, we demonstrate that    T cells play a critical role
in protective immune responses against tumor develop-
ment by providing such an early source of IFN- , which
in turn regulates tumor antigen–triggered CD4   and
CD8  T cell responses.
We first demonstrated that    T cells play a nonredun-
dant role in preventing tumor formation and tumor growth
in both primary and transplantable tumor models.    T
cells have been convincingly shown in many systems to
play a critical role in early pathogen protection (11, 30, 31).
Figure 5.    T cells regulate IFN- 
production by tumor antigen–triggered
   T cells. B6 and B6 TCR  /  mice
(n   5 for both strains) were immunized
with tumor lysates in CFA and rechal-
lenged in vitro with identically prepared
lysates for 24 h. Brefeldin A was added
for the last 4 h of culture and cells were
then used for intracellular cytokine
staining. After gating on CD3   and
CD8  T cells, the percentage of IFN- –
producing cells is shown. (A) The per-
centage of IFN- –producing cells from
both CD8  and CD4  cells is shown
(CD8 , lower left quadrant of dot plot shown in B). Data is mean   SD of five different mice. **, P   0.01; ***, P   0.05. (B) One example of intra-
cellular cytokine staining from wild-type (WT) and TCR  /  mice is shown.T
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Recently, Girardi et al. (22) have demonstrated a necessary
role for    T cells in cutaneous malignancy using TCR  / 
mice, with NKG-2D–mediated cytolytic activity proposed
as the antitumor mechanism. In agreement with these re-
sults, here we show that    T cells are able to retard tumor
growth in both a MCA fibrosarcoma (Fig. 1 A) and a mel-
anoma model (Fig. 1 B). A lack of    T cells rendered mice
significantly more susceptible to a chemical carcinogen and
to tumor cell inoculation compared with wild-type mice.
Moreover, TCR  /  mice had a tumor incidence similar
to TCR  /  and IFN-  /  mice, indicating a nonredun-
dant role for    T cells in protective tumor immune re-
sponses.
The most important finding presented in this report is
that IFN-  produced by    T cells is critical for a protec-
tive immune response against tumor development. Several
of our findings support this notion. First,    T cells were
the first group of T cells recruited into tumor injection site
(Fig. 2). It has been demonstrated in many infection sys-
tems that    T cells are among the first group of cells to ex-
pand and infiltrate at inflammatory sites (32, 33). Our re-
port finds for the first time that    T cells respond to tumor
cell insults earlier than    T cells. Moreover, these early
infiltrating    T cells (at day 3 after inoculation) produce
IFN-  ex vivo in the absence of extra stimulation (Fig. 2
D), strongly suggesting that the early source of IFN-  is
from    T cells. However, staining of tumor sites for IFN- 
was negative (unpublished data), likely a consequence of
the small amounts of locally produced cytokine or due to
the low avidity of anti–IFN-  antibodies. Nevertheless, our
results, together in the setting of the ability of    T cells to
recognize antigens without the need for engagement of
conventional antigen processing pathways and their default
production of IFN- , led us to believe that the early inter-
action between    T cells and tumor cells might provide
the early source of IFN-  for subsequent    T cell activa-
tion and differentiation.
To directly address this issue, we constructed mice with
an intact    and    T cell composition, except that the lat-
ter lacked the ability to produce IFN- . The advantage of
these animals is that we could directly assess our hypothesis
that the IFN-  produced by    T cells is a critical early
source for tumor immunity, in a physiological setting. Our
bone marrow chimeras had a composition of    and    T
cells similar to wild-type mice (Fig. 3 A), although we pro-
duced animals in which    T cells could or could not pro-
duce IFN-  (Fig. 3 B). A similar phenotype was observed
in mice selectively reconstituted with fetal liver cells (un-
published data). Using these mice, we demonstrated that
IFN-  made by    T cells resulted in susceptibility to both
MCA-induced tumors (Fig. 4 A) and B16 melanoma cell
inoculation (Fig. 4, B–D). This finding strongly supports
our hypothesis that    T cells are indeed the early source of
IFN-  for protective immune responses against tumor for-
mation and tumor growth.
Finally, IFN-  produced by    T cells appeared to mod-
ulate CD4  and CD8  IFN-  production. Depletion of   
T cells resulted in significantly reduced IFN-  production
by both CD4  and CD8  T cells upon challenge with tu-
mor antigen (Fig. 5), indicating that early production of
IFN-  by    T cells enhanced subsequent IFN-  produc-
tion by    T cells. Without    T cell synthesis of IFN- ,
the adaptive immune response was impaired, leading to en-
hanced tumor susceptibility.
NK and NK T cells have also been shown to play an
important role in tumor immunosurveillance, in part de-
pendent on IFN-  production (34–36). Although NK and
NK T cells are intact in our TCR  /  mice, the fact that
these mice remain highly susceptible to MCA or B16 mel-
anoma inoculation may be explained by the following pos-
sibilities. First, NK and NK T cells might be the down-
stream targets of    T cells and    T cells might be
required for the competent function of these cells, through
direct interaction or provision of IFN- . Second,    T
cells might be the target effector cells of NK and NK T
cells. Without    T cells the effector function of NK and
NKT cells might be impaired. Further analysis of the func-
tional states of NK or NK T cells in TCR  /  mice or in
our mice with selective depletion of IFN-  produced by
   T cells should further our understanding of the inter-
play between these cell populations.
It should be emphasized that    T cells might have other
antitumor mechanisms other than provision of IFN-  for
protective immune responses.     T cells from synovial
fluid of patients with Lyme arthritis are cytolytic toward a
wide array of target cells by a Fas–FasL interaction (37), and
human intestinal V 1    T cells directly recognize tumor
cells of epithelial origin (38). Recently, it has been demon-
strated that skin    T cells directly kill skin carcinoma cells
by an NKG-2D-Rae1/H60 interaction (22). However, it
is unclear at the present time whether    T cell cytolytic
function is correlated with, or requires, IFN-  production.
Further studies are needed to clarify whether these two ef-
fector arms overlap or if they are in parallel.
In summary, we have presented evidence that IFN- 
produced by    T cells is an essential early source of IFN- 
for tumor immunosurveillance, which in turn regulates   
T cell IFN-  production. These findings will not only shed
light on the molecular mechanisms of immunosurveillance,
but may also help in the design of novel therapeutic ap-
proaches via manipulation of the function of    T cells.
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